Core Viewpoint - Xinlitai (002294.SZ) has announced that its product, Aliskiren Tablets, has been included in the regular catalog of medical insurance under Category B management, reflecting the company's commitment to enhancing drug accessibility and meeting unmet clinical needs in the cardiovascular chronic disease sector [1] Group 1: Product Inclusion in Medical Insurance - Aliskiren Tablets have been included in the medical insurance catalog under Category B management [1] - Other products such as Rolitin (Aliskiren Amlodipine Tablets) and Xinlitin (Benzyl Acid Faglitin Tablets) have previously been negotiated for inclusion in the medical insurance catalog and are still under valid agreements [1] Group 2: Focus on Chronic Disease Management - The company is focusing on the cardiovascular chronic disease field, particularly on Cardio-Renal Metabolic Syndrome (CKM) [1] - A differentiated product portfolio has been established to address various pathogenesis and patient classification characteristics in hypertension, covering the entire treatment needs from primary hypertension without complications to diseases with cardio-renal target organ damage [1] Group 3: Innovation and Market Strategy - Six new chronic disease drugs have been included in the medical insurance catalog through negotiations, demonstrating national support for innovative drugs with high clinical value [1] - The company aims to leverage policy opportunities to actively promote the inclusion of negotiated drugs in hospitals and market coverage, continuously enhancing drug accessibility based on clinical value [1]

Core Viewpoint - The company, Sinopharm, has successfully negotiated the inclusion of its drugs in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List for 2025, which is expected to enhance market access and sales potential for these products [1] Group 1: Drug Inclusion in Insurance List - The drugs Xinchaotuo (Sacubitril/Valsartan) and Fuli'an (Aliskiren and Indapamide Sustained-release Tablets) have been newly included in the Class B category of the insurance list [1] - The drug Ennaruo (Entresto) has successfully renewed its contract to remain in the insurance list [1] - The drug Xinlitai (Aliskiren Tablets) has been adjusted to regular management under the insurance directory [1] Group 2: Previous Negotiations - The drugs Fuli'an (Aliskiren and Indapamide Sustained-release Tablets) and Xinliting (Bempedoic Acid Tablets) were previously included in the insurance list through negotiations and are still under valid agreements, classified under Class B [1]

Core Insights - The innovative drug Rulitan® (generic name: Aliskiren Indapamide Sustained-release Tablets) has been launched on JD Health, marking a significant advancement in hypertension treatment in China [1][2] - Rulitan® is the first ARNI + thiazide-like diuretic fixed-dose combination antihypertensive drug developed exclusively by the company, utilizing a triple mechanism for blood pressure reduction [1] - The prevalence of hypertension among adults in China is approximately 27.5%, highlighting a substantial market opportunity for effective treatment options [1] Company Strategy - The company plans to strategically cover various segments of hypertension patients with Rulitan®, complementing its existing products such as Xintan® (Aliskiren Tablets), Xinchao® (Sacubitril Aliskiren Calcium Tablets), and Rulitan® (Aliskiren Amlodipine Tablets) [2] - The collaboration with JD Health aims to enhance the accessibility of innovative drugs, addressing clinical needs and benefiting a larger patient population [2] Market Context - Hypertension is a systemic disease that can lead to severe complications such as stroke, coronary heart disease, heart failure, and renal failure, emphasizing the importance of effective treatment options [1] - The drug is particularly suitable for patients with salt-sensitive hypertension, elderly patients, and those with comorbidities such as diabetes and metabolic syndrome [1]

Group 1 - The new hypertension treatment drug, Xinchaotuo® (Sacubitril/Alesartan Calcium Tablets), has been launched online by JD Health and is the first original ARNI (Angiotensin Receptor Neprilysin Inhibitor) antihypertensive drug developed in China, offering superior and safer blood pressure control [2] - Xinchaotuo® is the first ARNI drug developed in China and the second ARNI co-crystal drug globally, featuring a design that synchronizes the peak effects of its active metabolite, Sacubitril, and Alesartan, thereby extending the half-life of Alesartan and improving blood pressure control [2] - ARNI drugs not only provide effective blood pressure reduction but also offer heart and kidney protection, making them particularly suitable for patients with hypertension combined with heart failure or chronic kidney disease [2] Group 2 - Xinli Tai Pharmaceutical has strategically focused on the hypertension treatment area, developing a complete family of original Alesartan antihypertensive drugs, including single-agent and combination formulations [3] - JD Health aims to leverage its capabilities to help Xinchaotuo® reach a broader patient base, enhancing the treatment level for hypertension in China through this collaboration [3] - JD Health has been recognized as the "first station for the online launch of new specialty drugs," continuously expanding its value effect and providing innovative drug access to a wide range of patients [3]